Thus, interfering with the eIF2α phosphorylation/dephosphorylation cycle could represent an interesting pharmacological strategy to limit systemic inflammation and liver failure during endotoxemia. The gene discussed is EIF2A; the disease is serum lipopolysaccharide activity.